1,721,003 research outputs found
Hyaluronic acid in obstetrics: role in Physiological Pregnancy
No full textPregnancy is a physiologically fine-balanced condition, characterized by radical hormonal and physical changes necessary for successful blastocyst implantation, optimal embryo development and safe birth. During gestation, several biological modifications are adopted by maternal body to accept the fetus (e.g., immune tolerance). In this context, Hyaluronic Acid (HA) is an interesting molecule, seemingly involved in many steps of the process, with a pivotal role in ovulation, fertilization, blastocyst implantation, inhibition of uterine contraction, immunomodulation of T cells or labour-related cervical modifications
Integration and phytodrugs in the treatment of obstetric-gynecological diseases: Modena, March 8, 2008. Presentation
No full textThe establishment of the experts group on inositol in basic and clinical research (EGOI), a scientific association of the foremost experts on inositol applications
Full text link
Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
No full textThe outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection
PCOS and infertility. Metformin administration and ovulation induction in patients with reproductive failures. Preliminary data.
Full text linkThe aim of this study is to investigate the effects of the metformin administration in patients with previous reproductive failures.
Inclusion criteria: 13 patients with chronic anovulation and PCOS, age < 38 years old, sterility not less than 2 years, C.C. resistance, conception failure in previous cycles with only r-FSH and negativity to the multiple miscarriages tests, absence of others infertility factors.
Metformin administration started 2 months before the ovulation induction.
Alternatively a spontaneous menstruation it was induced by progestin.
Ovulation was performed with r-FSH and patients were invited to have sexual intercourse during the 48h after the HCG trigger. Luteal support was administrated.
Results showed 100% of ovulatory cycles, 5 pregnancies and only 1 lost.
Few side effects
Diclofenac pyrrolidine versus Ketoprofen for the relief of pain from episiotomy: A randomized controlled trial
No full textBackground. The treatment of pain from episiotomy or from tearing of perineal tissues during childbirth is often unapplied, although discomfort may be severe. We performed a randomized double-blind controlled trial to compare the effectiveness and side-effects of two analgesics in the management of postpartum perineal pain. Patient preference toward the two medications was also analyzed. Methods. A total of 261 women were randomly assigned to receive either Diclofenac hydroxyethyl pyrrolidine (100 mg) (n = 133) or Ketoprofen (100 mg) (n = 128), both given orally every 12 hr up to 48 hr, as necessary. Inclusion criteria were vaginal birth with episiotomy and/or a second- to third-degree tear. Pain ratings were recorded before the administration of the drugs and at 1, 4, 12, and 24 hr after the first dose, according to a 10-cm visual-analog scale. Side-effects and overall opinion on the two treatments were assessed at 24 hr. Results. Diclofenac hydroxyethyl pyrrolidine and Ketoprofen had similar analgesic properties in the first 24 hr postpartum [mean pain rating 3.1 +/- 1.8 and 3.4 +/- 2.0, mean number of doses in 24 hr 1.4 +/- 1.4 and 1.3 +/- 1.5, and proportion of treatment failures 12.8% (17/133) and 16.4% (21/128), respectively]. Significantly fewer subjects in the Diclofenac hydroxyethyl pyrrolidine group than in the Ketoprofen group experienced side-effects (6.8% versus 15.6%; p = 0.038) with an odd risk = 0.39(95% C.I. 0.16-0.95). There were no significant differences in overall patient satisfaction between the two groups. Conclusions. No main differences were found concerning the relief of pain between the two treatments. Diclofenac hydroxyethyl pyrrolidine may be the preferred choice because it is associated with less adverse reactions, together with a faster action in the relief of pain
Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials
No full textMetformin (MET), the most commonly used insulin sensitizer, is the reference off-label drug for the treatment of polycystic ovary syndrome (PCOS), worldwide. However, its use may be limited mainly by gastrointestinal adverse effects. Myo-inositol (MI), a well-recognized food supplement, also represents an evidence-based treatment for PCOS women, popular in many countries. Our aim is to provide a systematic review of the literature and a meta-analysis which compares these two treatments, for their short-term efficacy and safety in PCOS patients. Systematic review and meta-analysis of randomized clinical trials (RCTs). RCTs were identified from 1994 through 2017 using MEDLINE, Cochrane Library, PubMed, and ResearchGate. Included studies were limited to those one directly comparing MET to MI on several hormones changes. Standardized mean difference (SMD) or risk ratios (RRs) with 95% CIs were calculated. Changes in fasting insulin was the main outcome of measure. Six trials with a total of 355 patients were included. At the end of treatment, no difference between MET and MI was found on fasting insulin (SMD=0.08 μU/ml, 95% CI: −0.31–0.46, p=.697), HOMA index (SMD =0.17, 95% CI: −0.53–0.88, p=.635), testosterone (SMD= −0.01, 95% CI: −0.24–0.21, p=.922), SHBG levels (SMD= −0.50 nmol/l, 95% CI: −1.39–0.38, p=.263) and body mass index (BMI) (SMD= −0.22, 95% CI: −0.60–0.16, p=.265). There was strong evidence of an increased risk of adverse events among women receiving MET compared to those receiving MI (RR =5.17, 95% CI: 2.91–9.17, p<.001). No differences were found in the effect of MET and MI on short-term hormone changes. The better tolerability of MI makes it more acceptable for the recovery of androgenic and metabolic profile in PCOS women
- …
